Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers

Stopped early

Conditions studied: Atrial Fibrillation

In brief

The investigators are evaluating the effect of Pradaxa in comparison to warfarin on bone turnover and bone density in men and women with atrial fibrillation.

Key facts

Study ID

NCT02791555

Run by

UConn Health

People needed

2

Starts

2016-06-01

Expected to finish

2017-03-01

Last updated by the study team

2017-04-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 50 and above, male and female starting on Pradaxa or Warfarin for nonvalvular atrial fibrillation
• Able to ambulate independently and travel to UConn Health in Farmington CT-

You may not qualify if…

• Prior known history of osteoporosis
• Chronic kidney disease with creatinine clearance less than 30
• Serum 25 hydroxyvitamin D level less than 10
• Ongoing treatment with medications that interfere with bone metabolism such as steroids, bisphosonates, denosumab, estrogen, SERMS
• Hypercalcemia, a history of Paget's disease, a history of multiple myeloma, or a history of monoclonal gammopathy of uncertain significance -

Where it is running

• University of Connecticut Health Center — Farmington, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.